News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
careplusvn.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article is a statement of changes in beneficial ownership of securities for Officer Rosenthal Arnon of Alector. The content simply states "Document," indicating that the full details are likely contained within a linked or attached document.
Alector CEO Arnon Rosenthal sold 72,606 shares of Alector, Inc. stock for a total of $193,473 on September 3, 2026. The sale was made to cover tax obligations from vested restricted stock units. Despite the stock being up 58% year-to-date, InvestingPro analysis indicates the โฆ
Alector CFO Neil Berkley sold 29,251 shares of ALEC stock for a total of $77,948 to cover tax obligations from vested restricted stock units. Following the sale, Berkley still holds 350,649 shares. InvestingPro analysis suggests the stock is overvalued despite the company's strong cash โฆ
Grace Wong-Sarad, Principal Accounting Officer at Alector, Inc. (NASDAQ:ALEC), sold 9,446 shares of company stock in early September across three transactions, totaling approximately $24,665. The sales were made pursuant to a Rule 10b5-1 trading plan and to cover tax obligations. Following these transactions, Ms. โฆ
Alector, Inc., a biotechnology company specializing in neurodegenerative diseases, announced its participation in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Management will host fireside chats at both events, which will โฆ
This article provides an overview of Alector Inc.'s (ALEC) earnings history and trends, including EPS and revenue comparisons against Street estimates. It highlights a 100% EPS beat rate and an average EPS surprise of +28.53%. The report also includes detailed quarterly data for EPS โฆ
Alector, Inc. (ALEC) CEO Arnon Rosenthal transferred 2.1 million shares of common stock among family trusts on August 19, 2026, as reported in a Form 4 filing. The shares were gifted from The Rosenthal Family Revocable Trust to three separate 2007 family trusts at โฆ
Alector, Inc. (NASDAQ:ALEC) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $3.625 against a current share price of $2.15. Despite beating quarterly earnings expectations with a smaller loss and higher revenue, the company remains deeply unprofitable, โฆ
Analysts have significantly upgraded Alector, Inc.'s near-term revenue forecasts by 60%, with the consensus for 2026 now standing at US$11 million, despite an expected 21% reduction in sales over the past year. While losses per share are predicted to decrease by 19% to US$0.86, โฆ
TD Cowen has reiterated its Hold rating on Alector (ALEC.US). The report indicates the firm's continued assessment of Alector's stock.
HC Wainwright has lowered its Q3 and full-year 2026 earnings estimates for Alector, forecasting a deeper loss per share despite the company beating revenue expectations in its latest quarterly results. Alector's stock opened down 5.1% at $1.69, and analysts currently hold a consensus "Hold" โฆ
BofA Securities has reiterated its Sell rating for Alector (ALEC.US) and set a target price of $1.00. This analyst action reflects a continued bearish outlook on the company's stock by the firm.
Analysts have provided insights on several healthcare companies, including Alector (ALEC), Genmab (GMAB), and Xenon (XENE). Alector received a Hold rating from William Blair, with a consensus Hold rating and a significant upside potential. Genmab was rated Buy by TD Cowen and TipRanks โ โฆ
H.C. Wainwright has reiterated its Buy rating for Alector (ALEC.US) and maintained its target price at $5. This indicates continued confidence from the analyst firm in the company's prospects.
This article provides current stock news for Alector Inc (ALEC), a biotechnology and medical research company. As of the closing bell on August 7th, ALEC stock was trading at $1.780 USD, down 2.73%. The page indicates that more news regarding earnings, analyst ratings, and โฆ
Alector Inc (ALEC) has an earnings forecast score of 6.50, ranking 325 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $1.50, with a high of $5.00 and a low of $0.75, predominantly recommending a โฆ
Alector, Inc. reported its second-quarter 2026 results, showing a revenue of $3.32 million, a 57.8% decline year-over-year, and a net loss of $23 million, an improvement from the $30.5 million loss in the prior year. Diluted EPS improved to $(0.21) from $(0.30) YoY. The โฆ
This page provides comprehensive financial data, news, and analysis for Alector, Inc. (ALEC), a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. It includes real-time stock price information, historical performance, key statistics, analyst ratings, and a company overview detailing its pipeline of โฆ
Alector (NASDAQ: ALEC) reported better-than-expected Q2 earnings, with an EPS of $-0.21 against an analyst estimate of $-0.23, and revenue of $3.32M, surpassing the consensus of $2.12M. Despite the positive earnings, the company's stock has seen a -11.43% decline in the last three months, โฆ
Alector, Inc. reported its second-quarter 2026 financial results, highlighting $172.8 million in cash, cash equivalents, and investments, projected to fund operations through 2027. The company is advancing its Alector Brain Carrier (ABC) platform, with AL137 for Alzheimer's disease targeting an IND submission in Q1 โฆ
Alector Inc (ALEC) is projected to report a loss of 23 cents per share. This earnings preview suggests analysts are anticipating a negative financial outcome for the company in its upcoming report.
This article provides a detailed financial overview of Alector Inc. (ALEC), including its latest earnings report, key financial indicators like EPS, revenue, net profit, and balance sheet details. It also includes an analyst rating of "HOLD" and answers frequently asked questions regarding the company's โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States